Introduction {#s1}
============

More 150,000 patients with cancer are diagnosed with brain metastasis each year [@pone.0051713-Bovi1], with the lung being the most common primary site for secondary BM [@pone.0051713-Subramanian1], [@pone.0051713-Nathoo1]. Improved RT techniques and the increased use of combined-modality therapy have reduced distant metastases and significantly improved survival. However, it has shown to be associated with increased rates of overall brain failure [@pone.0051713-Gore1]. The outcome of the diagnosis of brain metastases is dismal. Even for young patients with good performance status and controlled extra-cranial disease, the median survival time for patients after the development of BM is only about 7 months [@pone.0051713-Gaspar1]. Means of preventing the development of BM are therefore urgently sought. For example, prophylactic cranial irradiation (PCI) has a clearly defined role in the treatment of high-risk patients with acute lymphocytic leukemia and patients with small-cell lung cancer (SCLC) [@pone.0051713-Slotman1]. These are radiosensitive tumors where moderate doses of radiation can be employed and result in significant improvements in intracranial control in addition to overall survival, and therefore PCI is considered standard of care. Perhaps patients with non-small cell lung cancer (NSCLC) as well. Prior randomized, controlled trials and several prospective studies without brain primary end points and retrospective studies evaluating PCI for NSCLC have consistently shown a decrease and/or delay in BM with PCI [@pone.0051713-Gore1], [@pone.0051713-Umsawasdi1], [@pone.0051713-Cox1], [@pone.0051713-Russell1]. But PCI has not become part of standard management for LA-NSCLC because of concern for long-term toxicity and lack of a proven survival benefit. It is unclear as to whether this is secondary to failure of identifying the cohort best suited for prevention. The authors of this paper hypothesized that among NSCLC patients of stage I-IV may exist a group of patients at high risk of presenting BM. This group should be identified in order to serve as target for future studies of PCI application in NSCLC and avoid side effects for those who at low risk of presenting BM.

Defining the cohort of high-risk patients is difficult, because it is dependent on reports that often have conflicting results. Pretreatment factors that predict for high rates of BM include histology, extent of disease, and young age. However, not all studies have shown a significant correlation [@pone.0051713-Cox2], [@pone.0051713-Ceresoli1], [@pone.0051713-Robnett1]. The expression levels of three genes, *CDH2* (N-cadherin), *KIFC1*, and *FALZ*, was found in one study to be highly predictive of BM in early and advanced lung cancer [@pone.0051713-GrinbergRashi1]. The expression levels of genes can be effect by other factors and not so precise which seriously limits this approach for risk prediction. Rarely study addressing the question about the association between polymorphisms and brain failure. Moreover, the heterogeneity and genetic complexity of NSCLC make it unlikely that any single SNP would be sufficient to confer the risk of BM. Rather, studying multiple SNPs in signaling pathways that regulate cell proliferation and migration may be a more powerful way of pinpointing the genes and polymorphisms involved in conferring risk of BM. One such pathway is that of transforming growth factor-β (TGF-β).

The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins, activins, and related proteins. TGF-β signaling pathways have diverse effects on cell proliferation, morphogenesis, migration, extracellular matrix production, and apoptosis. In particular, TGF-β suppresses early-stage tumor development by virtue of its potent growth inhibitory effect, but becomes a pro-oncogenic factor that stimulates tumor cell growth and invasiveness at later stages of tumorigenesis [@pone.0051713-Massague1], [@pone.0051713-Javelaud1]. Tumor cells can escape the antiproliferative effects of TGF-β by acquiring mutations in components of signaling pathways or by selectively disrupting TGF-β signaling. The epithelial-to-mesenchymal transition (EMT) is associated with cellular acquisition of motility and invasive properties that promote the formation of distant metastasis [@pone.0051713-Nguyen1]. A variety of other mechanisms, including changes in expression of cell-cell adhesion molecules and secretion of metalloproteinases, also contribute to the metastatic process [@pone.0051713-Meulmeester1].

Given the prominent role of the TGF-β pathway in maintaining cellular function and the effect of its disruption on distant metastasis, common genetic variations in this pathway may emerge as potential predictors of BM risk. In this study, we tested the hypothesis that common genetic variants in the TGF-β pathway are associated with BM risk, and we attempted to identify subgroups of patients with NSCLC who are at particularly high risk of developing BM.

Patients and Methods {#s2}
====================

Patient Population {#s2a}
------------------

Subjects in this study were selected from a total of 201 patients with lung cancer who had been treated at either the Tongji Hospital Cancer Center or the Hubei Provincial Tumor Hospital in 2008--2009 who also had blood samples available for analysis. All study participants provided written informed consent before blood samples were collected. The study was approved by the Ethics Committee of Tongji Medical College. Of these 201 patients, 190 had documentation having undergone complete disease staging, and 161 had pathologically confirmed NSCLC. These 161 patients were the basis of this analysis. Clinical data were obtained from patients' files. Disease had been staged in terms of the tumor/node/metastasis system in the sixth (2002) edition of the American Joint Committee on Cancer staging manual. The diagnosis of BM was based on computed tomography or magnetic resonance imaging records. The smoking status includes current, former, or never smoker. Former smokers were defined as individuals who had successfully ceased smoking for at least 1 year at the time of study registration. Never smokers were defined as individuals who had \<20 total cigarettes during their lifetime [@pone.0051713-Khuri1]. The time to BM was the interval from the date of NSCLC diagnosis to the date of BM diagnosis. The follow-up time was the interval from NSCLC diagnosis to death or to the last hospital visit.

Genotyping Methods {#s2b}
------------------

The procedures used to select SNPs in the TGF-β pathway have been described previously [@pone.0051713-Yuan1]. Briefly, we used databases at Gene Oncology (<http://www.geneontology.org>) and the National Center for Biotechnology Information (NCBI)'s Gene database (<http://www.ncbi.nlm.nih.gov/gene>) and related literature to identify all functional single nucleotide polymorphisms (SNPs) of the genes in TGF-β signaling pathways with a minor allele frequency of more than 0.05 in a Chinese population. We selected 33 SNPs in 13 genes related to TGF-β pathways that were either located in the promoter untranslated region or coding region of the gene or had been previously reported as being associated with survival, lung cancer, or general metastasis ([**Table 1**](#pone-0051713-t001){ref-type="table"}). Genomic DNA was isolated from peripheral blood lymphocytes by using the QuickGene DNA whole blood kit S (Fuji Film) and stored at --80°C until use. Thirty-two of the SNPs were genotyped by using MALDI-TOF mass spectrophotometry to detect allele-specific primer extension products with the MassARRAY platform (Sequenom, Inc.). Assay data were analyzed using Sequenom TYPER software (version 4.0). The individual call rate threshold was at least 95%. The 33^rd^ SNP (*TGFB1:* rs1800470) was genotyped by using the TaqMan assay [@pone.0051713-Hildebrandt1].

10.1371/journal.pone.0051713.t001

###### Genes and single-nucleotide polymorphisms (SNPs) selected for analysis.

![](pone.0051713.t001){#pone-0051713-t001-1}

  Gene(number of SNPs)        SNP       Allelic change
  ---------------------- ------------- ----------------
  *TGFB1* (3)             rs 4803455         A\>C
                          rs 1800469         C\>T
                          rs 1800470         C\>T
  *BMP1* (2)              rs 3857979         C\>T
                          rs 7838961         A\>G
  *BMP2* (1)               rs 235756         C\>T
  *BMP4* (2)               rs 17563          C\>T
                          rs 8014071         G\>T
  *INHBC* (1)             rs 4760259         C\>T
  *TGFBR1* (3)            rs 10819638        C\>T
                          rs 6478974         A\>T
                          rs 10733710        A\>G
  *ACVR2A* (1)            rs 1424954         A\>G
  *SMAD1* (1)             rs 11939979        A\>C
  *SMAD3* (7)             rs 4776342         A\>G
                          rs 12102171        A\>C
                          rs 6494633         C\>T
                          rs 11632964        C\>T
                           rs 750766         A\>G
                          rs 4776343         A\>G
                          rs 11071938        C\>T
  *SMAD4* (6)              rs 948588         A\>G
                          rs 12456284        A\>G
                          rs 7244227         A\>G
                          rs 12455792        C\>T
                          rs 12958604        A\>G
                          rs 10502913        A\>G
  *SMAD6* (3)             rs 12913975        A\>G
                          rs 12906898        A\>G
                          rs 4776318         A\>C
  *SMAD7* (1)             rs 7227023         A\>G
  *SMAD8* (2)             rs 7333607         A\>G
                           rs 511674         A\>G

NOTE. A total of 33 SNPs from 13 TGF-β pathway-related genes were genotyped.

Statistical Analysis {#s2c}
--------------------

This analysis was undertaken after all patients had been potentially observed for a minimum of 24 months. Patients were grouped according to genotype. Statistical analysis was performed using SPSS (version 16.0) software. Cox proportional hazards model was used to calculate hazard ratio (HR) and 95% confidence intervals (CIs) for multivariate survival analyses, while adjusting for sex, age, disease stage, tumor histology, Karnofsky performance status (KPS), and smoking status. Kaplan-Meier plots and log rank tests were used to estimate the effect of genotype on BM risk. Likelihood ratio tests were used for each multivariate Cox regression to assess goodness-of-fit. A *P* value of ≤0.05 was considered to indicate statistical significance in two-sided *t* tests.

Results {#s3}
=======

Patient Characteristics {#s3a}
-----------------------

Characteristics of the 161 patients (116 men and 45 women) are shown in [**Table 2**](#pone-0051713-t002){ref-type="table"}. The median age was 58 years (range, 32 to 80 years); 61% had stage ≤IIIA disease; 60% had adenocarcinoma, and 54% had smoked tobacco (71.6% in male and 8.9% in female).

10.1371/journal.pone.0051713.t002

###### Patient and disease characteristics and their association with brain metastasis.

![](pone.0051713.t002){#pone-0051713-t002-2}

  Characteristic                No. ofPatients (%)    HR     Univariate Analysis(95% CI)   *P* Value    HR     Multivariate Analysis (95% CI)   *P* Value
  ---------------------------- -------------------- ------- ----------------------------- ----------- ------- -------------------------------- -----------
  Sex                                                                                                                                          
  Female                             45 (28)         1.000                                             1.000                                   
  Male                               116 (72)        0.827          0.480--1.425             0.493     0.890            0.457--1.734              0.732
  Age, years                                                                                                                                   
  ≥60 years                                          1.000                                             1.000                                   
  \<60 years                                         1.185          0.709--1.980             0.517     0.990            0.585--1.674              0.970
  Median (range)                   58 (32--80)                                                                                                 
  Disease stage at diagnosis                                                                                                                   
  I, II, IIIA                         99(61)         1.000                                             1.000                                   
  IIIB, IV                            62(39)         3.796          2.247--6.412             0.000     3.786            2.228--6.431              0.000
  Tumor histology                                                                                                                              
  Squamous cell                       51(32)         1.000                                             1.000                                   
  Adenocarcinoma                      97(60)         1.968          1.060--3.656             0.032     1.610            0.828--3.129              0.161
  NSCLC, NOS                          13 (8)         0.895          0.255--3.140             0.862     0.945            0.261--3.423              0.931
  KPS                                                                                                                                          
  \>80                               22 (14)         1.000                                             1.000                                   
  80                                 87 (54)         1.560          0.655--3.717             0.315     1.046            0.425--2.577              0.921
  \<80                               52 (32)         1.538          0.617--3.830             0.355     1.277            0.502--3.245              0.608
  Smoking status/Tobacco use                                                                                                                   
  current                            62 (38)         1.000                                             1.000                                   
  former                             25 (16)         1.965          0.970--3.982             0.061     1.677            0.798--3.523              0.172
  never                              74 (46)         1.261          0.704--2.258             0.436     0.959            0.479--1.921              0.906

NOTE. Multivariate analyses were adjusted for all factors listed in Table.

Abbreviations: HR, hazard ratio; CI, confidence interval; NSCLC NOS, non-small cell lung cancer, not otherwise specified; KPS, Karnofsky performance status.

Brain Metastasis and Genotypes {#s3b}
------------------------------

The median time from NSCLC diagnosis to detection of BM was 7.5 months (range, 0 to 23 months). The median time was 10 months when patients who presented with BM were excluded. Associations between patient- and tumor-related characteristics and BM by univariate and multivariate analyses are shown in [**Table 2**](#pone-0051713-t002){ref-type="table"}. As expected, disease stage was associated with BM, with patients having stage IIIB or stage IV disease at higher risk of BM (*P*\<0.010). And patients with adenocarcinoma were associated with higher risk of BM by Cox hazard analyses (*P* = 0.032). However, the smoking status has no association with BM risk in this population.

[**Figure 1**](#pone-0051713-g001){ref-type="fig"} illustrate cumulative BM-free survival rates for all patients according to genotype. These rates remained lower for those with either the GG genotype of *SMAD6*: rs12913975 (*P* = 0.024, [**Figure 1A**](#pone-0051713-g001){ref-type="fig"}) or the TT genotype of *INHBC*: rs4760259 (*P* = 0.045, [**Figure 1B**](#pone-0051713-g001){ref-type="fig"}). When we analyze combined subgroups, these rates showed lower for those having both the GG genotype of *SMAD6*: rs12913975 and the TT genotype of *INHBC*: rs4760259 (*P* = 0.003, [**Figure 1C**](#pone-0051713-g001){ref-type="fig"}). Other 31 SNPs in the TGF-β pathway in [**Table 1**](#pone-0051713-t001){ref-type="table"} were also analyzed, but no significant correlation was found (*P* = 0.877, [**Figure 1D**](#pone-0051713-g001){ref-type="fig"} for *TGFB1*: rs4803455; date of other 30 selected SNPs not shown).

![Kaplan-Meier curves showing brain metastasis-free survival among patients with non-small cell lung cancer.\
Patients were stratified by genotypes. (A) *SMAD6*: rs12913975; (B) *INHBC*: rs4760259; (C) combined; (D) *TGFB1*: rs4803455. The GG genotype for rs12913975 and the TT genotype for rs4760259 were associated with significantly lower cumulative brain metastasis-free survival compared with the other genotypes.](pone.0051713.g001){#pone-0051713-g001}

[**Table 3**](#pone-0051713-t003){ref-type="table"} and [**4**](#pone-0051713-t004){ref-type="table"} lists the findings of Kaplan-Meier analyses of BM incidence according to genotype at 24 months from diagnosis. In general, BM developed more often in patients with the GG genotype of *SMAD6*: rs12913975 (43%) or the TT genotype of *INHBC*: rs4760259 (44%) compared with the GA (21%) or CT/CC genotypes (27%). These associations between genotype and BM were statistically significant for both subgroups. When we analyze combined subgroups, we can see having both GG (rs12913975) and TT (rs4760259) show a higher probability of BM (52% vs 28%, *P* = 0.003, [**Table 4**](#pone-0051713-t004){ref-type="table"}). Multivariate Cox proportional hazard analyses showed the GG genotype of *SMAD6*: rs12913975 and TT genotype of *INHBC*: rs4760259 to be associated with a significantly higher risk of brain metastasis (HR 2.540, 95% CI 1.204--5.359, *P* = 0.014; and HR 1.885, 95% CI 1.086--3.273, *P* = 0.024, respectively), after adjustment for stage, histology, age, and smoking status. When analyze combined subgroups, these rates showed higher for those having both the GG genotype of *SMAD6*: rs12913975 and the TT genotype of *INHBC*: rs4760259 (HR 2.353, 95% CI 1.390--3.985, *P* = 0.001). Moreover, when we repeated the analysis excluding the patients who had presented with BM at the diagnosis of NSCLC, the association between BM and both genotypes remained significant ([**Table 3**](#pone-0051713-t003){ref-type="table"} and [**4**](#pone-0051713-t004){ref-type="table"}). Similar analyses of the other 31 selected SNPs showed no associations between any other genotype and the incidence of BM ([**Table 5**](#pone-0051713-t005){ref-type="table"} and [**6**](#pone-0051713-t006){ref-type="table"}).

10.1371/journal.pone.0051713.t003

###### Associations between genotypes and brain metastases.
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  Polymorphisms andGenotypes    No. ofPatients (All)   No. ofEvents (%)    HR        95% CI      *P* Value   No. of Patients withoutBM at Diagnosis   No. of Events(%)    HR        95% CI      *P* Value
  ---------------------------- ---------------------- ------------------ ------- -------------- ----------- ---------------------------------------- ------------------ ------- -------------- -----------
  *SMAD6*: rs12913975                                                                                                                                                                          
  GA                                     38                 8 (21)        1.000                                                36                          6 (17)        1.000                 
  GG                                    122                52 (43)        2.540   1.204--5.359     0.014                      108                         38 (35)        2.577   1.086--6.117     0.032
  *INHBC*: rs4760259                                                                                                                                                                           
  CT or CC                               69                19 (27)        1.000                                                64                         14 (22)        1.000                 
  TT                                     91                40 (44)        1.885   1.086--3.273     0.024                       81                         30 (37)        1.961   1.032--3.727     0.040

NOTE. Multivariate analyses in this table were adjusted for Stage, Histology, Age, and Smoking status. Similar results were obtained when multivariate analyses were adjusted for all the factors listed in Table1 (data not shown).

Abbreviations: HR, hazard ratio; CI, confidence interval; BM, brain metastases.

10.1371/journal.pone.0051713.t004

###### Associations between genotypes and brain metastases.

![](pone.0051713.t004){#pone-0051713-t004-4}

  Polymorphisms and Genotypes           No. of Patients(All)   No. of Events(%)    HR        95% CI      *P* Value   No. of Patients WithoutBM at Diagnosis   No. of Events(%)    HR        95% CI      *P* Value
  ------------------------------------ ---------------------- ------------------ ------- -------------- ----------- ---------------------------------------- ------------------ ------- -------------- -----------
  Other                                          97                27 (28)        1.000                                                89                         19 (21)        1.000                 
  GG (rs12913975) And TT (rs4760259)             64                33 (52)        2.353   1.390--3.985     0.001                       56                         25 (45)        2.648   1.424--4.924     0.002

NOTE. Multivariate analyses in this table were adjusted for Stage, Histology, Age, and Smoking status. Similar results were obtained when multivariate analyses were adjusted for all the factors listed in Table1 (data not shown).

Abbreviations: HR, hazard ratio; CI, confidence interval; BM, brain metastas.

10.1371/journal.pone.0051713.t005

###### Associations between genotypes and brain metastases (the other 31 selected SNPs).

![](pone.0051713.t005){#pone-0051713-t005-5}

  Polymorphisms and Genotypes    No. of Patients (All)   No. of Events (%)    HR        95% CI      *P* value
  ----------------------------- ----------------------- ------------------- ------- -------------- -----------
  *TGFB1*: rs4803455                                                                               
  CA or AA                                96                  37(39)         1.000                 
  CC                                      62                  23(37)         1.137   0.670--1.929     0.634
  *TGFB1*: rs1800469                                                                               
  CT or CC                                118                 45(38)         1.000                 
  TT                                      41                  15(37)         1.222   0.674--2.216     0.510
  *TGFB1*: rs1800470                                                                               
  CT or TT                                112                 42(38)         1.000                 
  CC                                      45                  17(38)         1.180   0.662--2.103     0.575
  *BMP1*: rs3857979                                                                                
  CT or TT                                72                  23(32)         1.000                 
  CC                                      89                  37(42)         1.298   0.768--2.196     0.330
  *BMP1*: rs7838961                                                                                
  GA or GG                                75                  26(35)         1.000                 
  AA                                      86                  34(40)         1.165   0.693--1.959     0.564
  *BMP2*: rs235756                                                                                 
  TC or CC                                48                  19(40)         1.000                 
  TT                                      113                 41(37)         0.932   0.538--1.613     0.800
  *BMP4*: rs17563                                                                                  
  TC or CC                                88                  31(35)         1.000                 
  TT                                      73                  29(40)         0.920   0.541--1.565     0.759
  *BMP4*: rs8014071                                                                                
  AG or GG                                93                  38(41)         1.000                 
  AA                                      65                  22(34)         0.890   0.524--1.513     0.667
  *TGFBR1*: rs10819638                                                                             
  CT or TT                                102                 37(36)         1.000                 
  CC                                      59                  23(39)         1.394   0.812--2.393     0.229
  *TGFBR1*: rs6478974                                                                              
  TA or AA                                86                  29(34)         1.000                 
  TT                                      75                  31(41)         1.006   0.602--1.682     0.981
  *TGFBR1*: rs10733710                                                                             
  GA or AA                                69                  30(44)         1.000                 
  GG                                      91                  29(32)         0.690   0.407--1.171     0.169
  *ACVR2A*: rs1424954                                                                              
  GA or GG                                111                 42(38)         1.000                 
  AA                                      49                  18(37)         1.004   0.572--1.762     0.988
  *SMAD1*: rs11939979                                                                              
  CA or CC                                63                  24(38)         1.000                 
  AA                                      95                  35(37)         0.947   0.552--1.624     0.843
  *SMAD3*:rs4776342                                                                                
  AG or AA                                112                 42(38)         1.000                 
  GG                                      49                  18(37)         1.060   0.607--1.852     0.836
  *SMAD3*:rs12102171                                                                               
  CT or TT                                90                  34(38)         1.000                 
  CC                                      71                  26(37)         1.156   0.685--1.952     0.587
  *SMAD3*:rs6494633                                                                                
  CT                                      33                  11(33)         1.000                 
  CC                                      128                 49(38)         0.801   0.404--1.588     0.526
  *SMAD3*:rs11632964                                                                               
  TC or TT                                94                  37(39)         1.000                 
  CC                                      67                  23(34)         0.755   0.445--1.282     0.298
  *SMAD3*:rs750766                                                                                 
  AG or AA                                98                  35(36)         1.000                 
  GG                                      62                  25(40)         1.215   0.721--2.048     0.465
  *SMAD3*:rs4776343                                                                                
  AG                                      14                   6(43)         1.000                 
  GG                                      147                 54(37)         0.931   0.395--2.192     0.869
  *SMAD3*:rs11071938                                                                               
  TC or TT                                72                  27(38)         1.000                 
  CC                                      89                  33(37)         1.077   0.646--1.795     0.776
  *SMAD4*:rs948588                                                                                 
  GA or AA                                17                   9(53)         1.000                 
  GG                                      144                 51(35)         0.740   0.359--1.523     0.413
  *SMAD4*:rs12456284                                                                               
  AG or GG                                93                  34(37)         1.000                 
  AA                                      65                  24(37)         0.845   0.494--1.444     0.537
  *SMAD4*:rs7244227                                                                                
  AG or GG                                109                 41(38)         1.000                 
  AA                                      50                  19(38)         0.905   0.521--1.571     0.722
  *SMAD4*:rs12455792                                                                               
  CT or TT                                110                 45(41)         1.000                 
  CC                                      49                  15(31)         0.612   0.338--1.107     0.104
  *SMAD4*:rs12958604                                                                               
  AG or GG                                125                 47(38)         1.000                 
  AA                                      36                  13(36)         0.828   0.446--1.540     0.552
  *SMAD4*:rs10502913                                                                               
  AG or AA                                87                  32(37)         1.000                 
  GG                                      74                  28(38)         0.920   0.549--1.541     0.920
  *SMAD6*: rs12906898                                                                              
  AG or AA                                37                  13(35)         1.000                 
  GG                                      122                 47(39)         1.297   0.688--2.444     0.421
  *SMAD6*: rs4776318                                                                               
  CA or AA                                57                  20(35)         1.000                 
  CC                                      103                 40(39)         1.161   0.662--2.037     0.603
  *SMAD7*: rs7227023                                                                               
  GA                                       8                   4(50)         1.000                 
  GG                                      153                 56(37)         0.808   0.284--2.301     0.690
  *SMAD8*: rs7333607                                                                               
  AG                                      29                  12(41)         1.000                 
  AA                                      128                 48(38)         0.942   0.497--1.786     0.855
  *SMAD8*: rs511674                                                                                
  GA                                      30                  10(33)         1.000                 
  AA                                      131                 50(38)         1.341   0.678--2.653     0.399

NOTE. Multivariate analyses in this table were adjusted for Stage, Histology, Age, and Smoking status. Similar results were obtained when multivariate analyses were adjusted for all the factors listed in [Table 1](#pone-0051713-t001){ref-type="table"} (data not shown).

Abbreviations: HR, hazard ratio; CI, confidence interval.

10.1371/journal.pone.0051713.t006

###### Associations between genotypes and brain metastases, excluding those with brain metastases at initial diagnosis of non-small cell lung cancer (the other 31 selected SNPs).
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  Polymorphisms and Genotypes    No. of Patients (All)   No. of Events (%)    HR        95% CI      *P* value
  ----------------------------- ----------------------- ------------------- ------- -------------- -----------
  *TGFB1*: rs4803455                                                                               
  CA or AA                                85                  26(31)         1.000                 
  CC                                      57                  18(32)         1.257   0.680--2.326     0.466
  *TGFB1*: rs1800469                                                                               
  CT or CC                                105                 32(31)         1.000                 
  TT                                      38                  12(32)         1.335   0.679--2.628     0.402
  *TGFB1*: rs1800470                                                                               
  CT or TT                                100                 30(30)         1.000                 
  CC                                      41                  13(32)         1.187   0.608--2.320     0.615
  *BMP1*: rs3857979                                                                                
  CT or TT                                67                  18(27)         1.000                 
  CC                                      78                  26(33)         1.249   0.682--2.289     0.472
  *BMP1*: rs7838961                                                                                
  GA or GG                                69                  20(29)         1.000                 
  AA                                      76                  24(32)         1.138   0.622--2.083     0.676
  *BMP2*: rs235756                                                                                 
  TC or CC                                41                  12(29)         1.000                 
  TT                                      104                 32(31)         1.108   0.569--2.158     0.762
  *BMP4*: rs17563                                                                                  
  TC or CC                                77                  20(26)         1.000                 
  TT                                      68                  24(35)         1.312   0.707--2.435     0.389
  *BMP4*: rs8014071                                                                                
  AG or GG                                81                  26(32)         1.000                 
  AA                                      61                  18(30)         0.995   0.543--1.823     0.986
  *TGFBR1*: rs10819638                                                                             
  CT or TT                                91                  26(29)         1.000                 
  CC                                      54                  18(33)         1.555   0.832--2.907     0.166
  *TGFBR1*: rs6478974                                                                              
  TA or AA                                76                  19(25)         1.000                 
  TT                                      69                  25(36)         1.245   0.679--2.285     0.479
  *TGFBR1*: rs10733710                                                                             
  GA or AA                                62                  23(37)         1.000                 
  GG                                      83                  21(25)         0.644   0.350--1.185     0.157
  *ACVR2A*: rs1424954                                                                              
  GA or GG                                102                 33(32)         1.000                 
  AA                                      42                  11(26)         0.757   0.376--1.523     0.436
  *SMAD1*: rs11939979                                                                              
  CA or CC                                56                  17(30)         1.000                 
  AA                                      86                  26(30)         0.989   0.526--1.860     0.974
  *SMAD3*: rs4776342                                                                               
  AG or AA                                102                 32(31)         1.000                 
  GG                                      43                  12(28)         0.928   0.475--1.811     0.826
  *SMAD3*: rs12102171                                                                              
  CT or TT                                79                  23(29)         1.000                 
  CC                                      66                  21(32)         1.303   0.711--2.386     0.392
  *SMAD3*: rs6494633                                                                               
  CT                                      31                   9(29)         1.000                 
  CC                                      114                 35(31)         0.737   0.340--1.594     0.437
  *SMAD3*: rs11632964                                                                              
  TC or TT                                84                  27(32)         1.000                 
  CC                                      61                  17(28)         0.736   1.395--1.372     0.335
  *SMAD3*: rs750766                                                                                
  AG or AA                                89                  26(29)         1.000                 
  GG                                      55                  18(33)         1.218   0.661--2.243     0.527
  *SMAD3*: rs4776343                                                                               
  AG                                      13                   5(38)         1.000                 
  GG                                      132                 39(30)         0.780   0.304--2.001     0.605
  *SMAD3*: rs11071938                                                                              
  TC or TT                                63                  18(29)         1.000                 
  CC                                      82                  26(32)         1.274   0.696--2.331     0.432
  *SMAD4*: rs948588                                                                                
  GA or AA                                14                   6(43)         1.000                 
  GG                                      131                 38(29)         0.725   0.300--1.753     0.476
  *SMAD4*: rs12456284                                                                              
  AG or GG                                84                  25(30)         1.000                 
  AA                                      59                  18(31)         0.884   0.473--1.651     0.699
  *SMAD4*: rs7244227                                                                               
  AG or GG                                99                  31(13)         1.000                 
  AA                                      44                  13(30)         0.821   0.424--1.587     0.821
  *SMAD4*: rs12455792                                                                              
  CT or TT                                98                  33(34)         1.000                 
  CC                                      45                  11(24)         0.596   0.298--1.192     0.143
  *SMAD4*: rs12958604                                                                              
  AG or GG                                112                 34(30)         1.000                 
  AA                                      33                  10(30)         0.897   0.438--1.837     0.767
  *SMAD4*: rs10502913                                                                              
  AG or AA                                79                  24(30)         1.000                 
  GG                                      66                  20(30)         0.893   0.487--1.638     0.714
  *SMAD6*: rs12906898                                                                              
  AG or AA                                34                  10(29)         1.000                 
  GG                                      109                 34(31)         1.226   0.592--2.539     0.583
  *SMAD6*: rs4776318                                                                               
  CA or AA                                52                  15(29)         1.000                 
  CC                                      92                  29(32)         1.161   0.609--2.216     0.650
  *SMAD7*: rs7227023                                                                               
  GA                                       7                   3(43)         1.000                 
  GG                                      138                 41(30)         0.774   0.232--2.590     0.678
  *SMAD8*: rs7333607                                                                               
  AG                                      25                   8(32)         1.000                 
  AA                                      116                 36(31)         1.043   0.480--2.265     0.916
  *SMAD8*: rs511674                                                                                
  GA                                      28                   8(29)         1.000                 
  AA                                      117                 36(31)         1.282   0.592--2.777     0.529

NOTE. Multivariate analyses in this table were adjusted for Stage, Histology, Age, and Smoking status. Similar results were obtained when multivariate analyses were adjusted for all the factors listed in Table1 (data not shown).

Abbreviations: HR, hazard ratio; CI, confidence interval.

Discussion {#s4}
==========

In this study, we systematically evaluated associations between a comprehensive panel of genetic variants in TGF-β signaling pathway genes and BM risk. We found that SNPs in *SMAD6*: rs12913975 GG or *INHBC*: rs4760259 TT were associated with the incidence of BM. To the best of our knowledge, this is the first evidence showing this association in patients with lung cancer. With validation, this test could be used as a predictive biomarker to identify patients at high risk of developing brain metastasis during the first 24 months after diagnosis.

One of the polymorphisms we found to be associated with BM risk was in *SMAD6*, which encodes a protein that localizes to both nuclei and cytoplasm. Smad6 and Smad7 act as "inhibitory" Smads, inhibiting TGF-β family signaling [@pone.0051713-Derynck1]. Induction of Smad6 and Smad7 expression by bone morphogenic protein and TGF-β signaling represents an auto-inhibitory feedback mechanism in the TGF-β pathway [@pone.0051713-Derynck1]. *SMAD6* is expressed in most human tissues, including the lung, but its function in tumorigenesis is not yet established. A previous retrospective study showed that *SMAD7* overexpression is linked with a reduced incidence of bone metastases from melanoma and breast cancer [@pone.0051713-Javelaud2]. The structural similarity between SMAD6 and SMAD7 proteins suggests that both proteins may be involved in metastasis via similar mechanisms. Variants in *SMAD6* have been linked with prognosis in ovarian cancer [@pone.0051713-LePage1], breast cancer and pancreatic carcinoma; polymorphism in *SMAD6* have also been linked with survival in NSCLC [@pone.0051713-Lin1]. Metastases, especially brain metastases, is an important factor associated with poor prognosis, and SNPs in *SMAD6* may contribute to metastases, include CNS metastases.

We also found *INHBC*: rs4760259 polymorphisms to be associated with BM risk. The *INHBC* gene is located on human chromosome 12, region q13.1, and encodes a protein named βC, belonging to the inhibin subgroup. Inhibin and activin proteins, along with various growth and differentiation factors, Muellerian inhibiting substance, and other proteins, belong to the TGF-β superfamily. Activins have many effects on mesoderm formation [@pone.0051713-McDowell1], cell proliferation and apoptosis [@pone.0051713-Hully1], branching morphogenesis [@pone.0051713-Ball1], inflammation [@pone.0051713-Jones1] and reproduction [@pone.0051713-deKretser1]. One α-subunit and four β-subunit isoforms (βA, βB, βCand βE) have been found in mammals and humans [@pone.0051713-Xia1]. The activin α, βA, and βB subunits and their homo−/heterodimers have been well characterized; activin A (βAβA), for example, is a pleiotropic protein that affects apoptosis, cell-cycle control, angiogenesis and immune suppression [@pone.0051713-Butler1]. The precise role of the βC subunit, however, is unclear. Activin βC subunit mRNA has been detected in rat and mouse lung, epididymis, testis, uterus, spleen, posterior pituitary, and adrenal gland, and in human ovary, testis, placenta, and prostate [@pone.0051713-Butler1]. The activin βC subunit or its dimers may oppose the action of activin A. In one in vitro study, the activin βC subunit had a pro-apoptotic effect in liver cell lines. Furthermore, the activin βC subunit was downregulated in prostate and liver tumor cell lines [@pone.0051713-Vejda1]. Transfection of the activin βC subunit into the PC3 prostate cancer cell line results in decreased activin A levels [@pone.0051713-Mellor1]. A recent study showed polymorphisms in *INHBC* is associated with ovarian cancer risk [@pone.0051713-Yin1]. Another study showed it to be strongly associated with survival in NSCLC [@pone.0051713-Lin1]. It can be seen that activin βC subunit is associate with tumorigenesis and progress, and metastases is a important step in tumor progression which strongly associated with poor prognosis, therefore we can believe SNPs in *INHBC* may contribut to BM.

A single SNP often provides a modest or undetectable effect whereas the amplified effects of combined SNPs in the same pathway may enhance predictive power. We analyzed the association with BM in patients with both two genotypes. A clear and significant trend was evident for higher risk with the combined subgroups. These results suggest a cumulative influence by multiple genetic variants within the TGF-β signaling pathway were able to further enhance predictive power.

However, neither of the SNPs we identified as being linked with BM is located in the coding region, which suggest that these SNPs may not affect *SMAD6* or *INHBC* function directly but rather may change levels of gene expression through being located in regulatory regions or through linkage to other SNPs that affect gene activity. Further in vitro and in vivo functional studies are needed to confirm the functional significance of the identified *SMAD6* and *INHBC* SNPs.

Moreover, we found that 48% of patients with both high risk alleles do not have brain metastasis ([**Table 4**](#pone-0051713-t004){ref-type="table"}), and 1.7% (1/60) of patients with brain metastasis do not carry either of the two high risk genotypes. As the heterogeneity and genetic complexity of NSCLC, we speculate that a few other factors and SNPs in other signaling pathways that regulate cell proliferation and migration may be also associated with the risk of BM. Future research are needed to further enhance predictive power.

PCI is considered part of standard therapy for limited-stage SCLC, as up to 80% of these patients develop BM [@pone.0051713-Auperin1], [@pone.0051713-Meert1]. Slotman et al. conducted a trial of 286 patients with extensive-stage SCLC who were randomized to receive either PCI or no PCI. Survival at 1 year improved from 13.3 to 27.1% [@pone.0051713-Slotman1]. At this time, nearly all patients with SCLC should be offered PCI to reduce the chance of BM and improve overall survival. Currently, the intensity of prophylactic therapy for acute lymphoblastic leukemia is adjusted to the risk of central nervous system (CNS) relapse [@pone.0051713-Pui1]. Prior randomized, controlled trials [@pone.0051713-Umsawasdi1], [@pone.0051713-Cox1], [@pone.0051713-Russell1] and several prospective studies evaluating PCI for NSCLC have been published. Studies have significantly show that PCI administered to patients improves intracranial disease control. However, none of these studies have ever shown a survival benefit with the application of PCI. The most recent RTOG trial (0214) evaluating the role of PCI in LA-NSCLC unfortunately closed early due to poor accrual. While there was a promising outcome in decreased intracranial metastases in the treatment group, this failed to result in a survival benefit [@pone.0051713-Gore1]. Joseph A et al. analyzes it is unclear as to whether this is secondary to failure of identifying the cohort best suited for prevention, the inability of radiation to effect sufficient intracranial disease prevention because of a relatively radio-resistent tumor, or the need for more effective systemic therapies to control extracranial disease so that patients' survival is long enough to see the benefit of PCI [@pone.0051713-Bovi1]. Because there is no predictive test to identify patients with high risk of brain metastatic, PCI has been given unselectively to all patients. PCI could negatively affect neurocognitive function and quality of life in those patients who do not need PCI [@pone.0051713-Gore1]. If the findings from current study are validated in a study with adequate statistical power prospectively, we could use the SNPs identified in this study as a pretreatment test to select patients who would benefit from PCI, while avoiding PCI in patients who do not need it.

Our study had some limitations. The small number of patients raises the possibility that some of our findings were due to chance. Future studies are necessary to identity functional significance of the genetic variants we have identified, as well as to confirm or externally evaluate the associations in independent populations.

Conclusions {#s4a}
-----------

We found that the GG genotype of *SMAD6*: rs12913975 and the TT genotype of *INHBC*: rs4760259 were associated with the incidence of BM in patients with NSCLC. These findings were confirmed in both Kaplan-Meier and multivariate Cox proportional hazard analyses, the latter adjusted for disease stage, tumor histology, age, and smoking status of the patient. These findings may be useful in future efforts to identify patients at high risk of brain metastasis.
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